Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

CYPH vs EBS: stock comparison and AI forecast

Cypherpunk Technologies Inc. (CYPH) and Emergent Biosolutions Inc. (EBS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

CYPH Cypherpunk Technologies Inc.

Market Cap
$310M
P/E Ratio
4.4x
Size
small-cap
AI Forecast
Full analysis →
NYSE · Pharmaceutical Preparations

EBS Emergent Biosolutions Inc.

Market Cap
$311M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

CYPH · EBS

Key facts

  • CYPH and EBS have similar market capitalizations ($310M and $311M).
  • EBS carries 2.18 times debt per unit of equity, against 0.03 times for CYPH.
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricCYPHEBS
Market Cap$310M$311M
P/E Ratio4.43x–
P/B Ratio2.23x0.99x
EPS$0.65$-3.97
Book Value/Share$1.29$6.11
Revenue/Share–$12.66
FCF/Share–$3.67

Profitability & Margins

MetricCYPHEBS
ROE-0.6%-83.2%
ROA-0.6%-26.2%
ROIC-12.6%-20.6%
Gross Margin–48.4%
Operating Margin–-27.7%
Net Margin–-40.2%
EBT Margin–-37.0%
Tax Rate108.0%-8.6%

Financial Health

MetricCYPHEBS
Current Ratio79.19x4.58x
Quick Ratio–2.27x
D/E Ratio0.03x2.18x
Financial Leverage1.03x3.18x
Interest Coverage-2788.6x-1.3x
Working Capital$136M$436M

Cash Flow

MetricCYPHEBS
Operating Cash Flow-$21M$200M
Free Cash Flow–$188M
Capital Spending–-$12M
OCF Growth YoY–1439.2%
FCF Growth YoY–13357.1%
FCF/Sales–29.0%
CapEx/Sales–1.8%

Operational Efficiency

MetricCYPHEBS
Asset Turnover–0.65x
Receivables Turnover–8.4x
Inventory Turnover–1.2x
Fixed Assets Turnover–3.7x
Days Sales Outstanding–44 days
Days Inventory–306 days
Payables Period–57 days
Cash Conversion Cycle–293 days

Income Statement

MetricCYPHEBS
Total Revenue–$649M
Operating Income-$18M-$180M
Net Income-$880K-$261M
R&D Expense$3M$41M
SG&A Expense–$189M
Cost of Goods Sold–$335M

Dividend & Shareholder Information

MetricCYPHEBS
Shares Outstanding108M51M
Net Income Growth–-443.5%
EPS Growth–-730.2%
FAQ

CYPH vs EBS: stock comparison and AI forecast

Which is bigger, CYPH or EBS?

CYPH and EBS have similar market capitalizations ($310M and $311M).

Which one does Intratio's AI model rank higher, CYPH or EBS?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.